Ascelis Center of Excellence for Peptide Development and Characterization, established under Ascelis Peptides, the CDMO arm of Granules, will drive the development of cosmetic, therapeutic and pharmaceutical peptides. It is Ascelis’ first development and characterization facility in India and is equipped for the characterization of primary, secondary and tertiary structures.
The center brings advanced analytical and process development capabilities in-house and will collaborate with our Swiss-based R&D facility Senn Chemicals, strengthening the group’s integrated global peptide offering and reducing dependence on external partners.
Granules Center of Excellence for Particle Engineering will advance polymorph research, materials science and novel drug delivery systems, including amorphous solid dispersions. It replaces previous external and ad hoc developments with a dedicated research platform that enables first-to-file capabilities, improves formulation performance and supports the creation of proprietary technologies for regulated markets.
“The launch of these Centers of Excellence significantly strengthens our capabilities in peptides and advanced materials sciences, areas that will define the next wave of pharmaceutical innovation,” Krishna Prasad Chigurupati, chairman and managing director of Granules India, said in a press release.
“With specialized infrastructure and deep scientific expertise, we are strengthening our CDMO ambitions, accelerating breakthrough developments and building differentiated technologies that increase our global competitiveness and deliver meaningful value to our partners and patients worldwide,” he added.
Published on December 1, 2025
#Granules #India #opens #CoEs #IIT #Hyderabad